Charles River Laboratories International, Inc. (CRL) Position Reduced by Affinity Investment Advisors LLC

Affinity Investment Advisors LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 13.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,210 shares of the medical research company’s stock after selling 2,910 shares during the quarter. Affinity Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $1,967,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Charles River Laboratories International by 0.5% during the second quarter. Vanguard Group Inc. now owns 5,060,730 shares of the medical research company’s stock worth $511,893,000 after purchasing an additional 27,217 shares during the last quarter. BlackRock Inc. lifted its stake in Charles River Laboratories International by 4.6% during the second quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock worth $406,913,000 after purchasing an additional 177,239 shares during the last quarter. FMR LLC lifted its stake in Charles River Laboratories International by 23.8% during the second quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock worth $311,458,000 after purchasing an additional 591,066 shares during the last quarter. State Street Corp lifted its stake in Charles River Laboratories International by 2.3% during the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock worth $128,288,000 after purchasing an additional 28,365 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Charles River Laboratories International by 14.4% during the second quarter. Renaissance Technologies LLC now owns 1,219,883 shares of the medical research company’s stock worth $123,391,000 after purchasing an additional 153,374 shares during the last quarter. Institutional investors and hedge funds own 97.63% of the company’s stock.

In other Charles River Laboratories International news, insider William D. Barbo sold 4,000 shares of the firm’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $99.91, for a total value of $399,640.00. Following the completion of the sale, the insider now owns 20,424 shares of the company’s stock, valued at $2,040,561.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David Ross Smith sold 2,552 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $67.10, for a total transaction of $171,239.20. Following the completion of the sale, the insider now directly owns 11,671 shares of the company’s stock, valued at approximately $783,124.10. The disclosure for this sale can be found here. In the last three months, insiders sold 18,699 shares of company stock valued at $1,892,393. 2.20% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: This report was posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2017/11/03/charles-river-laboratories-international-inc-crl-position-reduced-by-affinity-investment-advisors-llc.html.

Several equities research analysts have issued reports on CRL shares. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 price target for the company in a research note on Wednesday, July 12th. Barclays PLC reaffirmed a “hold” rating and set a $102.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. BidaskClub lowered Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Robert W. Baird reaffirmed a “buy” rating and set a $114.00 price target on shares of Charles River Laboratories International in a research note on Friday, September 1st. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $120.00 price target on shares of Charles River Laboratories International in a research note on Tuesday, September 12th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Charles River Laboratories International currently has an average rating of “Buy” and an average target price of $103.77.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.07. The company had revenue of $469.13 million during the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same quarter last year, the business posted $1.20 earnings per share.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

What are top analysts saying about Charles River Laboratories International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Charles River Laboratories International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit